Volume 14.36 | Sep 16

Cell Therapy News - Your Industry in an Instant
Your Industry in an InstantTwitter Facebook
Publications | Reviews | Science | Policy | Business | NIH | CBER | Regulatory | Events | Jobs
 
TOP STORY
Reprogramming In Vivo Produces Teratomas and Induced Pluripotent Stem Cells with Totipotency Features
The authors showed that transitory induction of the four factors Oct4, Sox2, Klf4 and c-Myc in mice results in teratomas emerging from multiple organs, implying that full reprogramming can occur in vivo. Analyses of the stomach, intestine, pancreas and kidney revealed groups of dedifferentiated cells that express the pluripotency marker NANOG, indicative of in situ reprogramming. By bone marrow transplantation, they demonstrated that hematopoietic cells can also be reprogrammed in vivo. [Nature] Abstract | Press Release
A New System for High-Throughput Cell Isolation Directly from Whole Blood
 
PUBLICATIONS (Ranked by impact factor of the journal)
Impact of Intracoronary Bone Marrow Cell Therapy on Left Ventricular Function in the Setting of ST-Segment Elevation Myocardial Infarction: A Collaborative Meta-Analysis
Scientists examined the effect of intracoronary bone marrow cell therapy on left ventricular function after ST-segment elevation myocardial infarction in various subgroups of patients by performing a collaborative meta-analysis of randomized controlled trials. [Eur Heart J] Abstract

Infusion of Donor-Derived CD19-Redirected-Virus-Specific T Cells for B-Cell Malignancies Relapsed after Allogeneic Stem Cell Transplant: A Phase I Study
After allogeneic hematopoietic stem cell transplantation, infused donor-derived virus-specific T cells (VSTs) expand in vivo, persist long-term and have anti-viral activity without inducing graft versus host disease; therefore, scientists determined whether donor VSTs, engineered to express CD19-specific chimeric antigen receptor, retained the characteristics of non manipulated allogeneic VSTs whilst gaining anti-tumor activity. [Blood] Abstract

Priming with Ligands Secreted by Human Stromal Progenitor Cells Promotes Grafts of Cardiac Stem/Progenitor Cells after Myocardial Infarction
Scientists hypothesized that secreted factors in conditioned medium from adult bone marrow-derived multipotent stromal cells could be used to prime adult cardiac stem/progenitor cells and improve graft success after myocardial infarction. [Stem Cells] Abstract

The Use of ASCs Engineered to Express BMP2 or TGF-β3 within Scaffold Constructs to Promote Calvarial Bone Repair
Although calvarial bone forms via intramembranous ossification without cartilage templates, it was previously suggested that chondrocytes/cartilages promote calvarial healing, thus the authors hypothesized that inducing adipose-derived stem cells (ASCs) chondrogenesis and endochondral ossification involving cartilage formation can improve calvarial healing. [Biomaterials] Abstract

Full-Length Dysferlin Expression Driven by Engineered Human Dystrophic Blood-Derived CD133+ Stem Cells
Antisense oligonucleotides-treated blood-derived CD133+ stem cells isolated from patients with Miyoshi myopathy led to partial dysferlin reconstitution in vitro, but failed to express dysferlin after intramuscular transplantation into scid/blAJ dysferlin null mice. Researchers extended these experiments producing the full-length dysferlin mediated by a lentiviral vector in blood-derived CD133+ stem cells isolated from the same patients. Transplantation of engineered blood-derived CD133+ stem cells into scid/blAJ mice resulted in sufficient dysferlin expression to correct functional deficits in skeletal muscle membrane repair. [FEBS J] Abstract

Mesenchymal Stem Cell Transplantation for the Infarcted Heart: Therapeutic Potential for Insulin Resistance Beyond the Heart
Investigators evaluated the efficacy of mesenchymal stem cell transplantation to mitigate abnormalities in cardiac-specific and systemic metabolism mediated by a combination of a myocardial infarction and diet-induced insulin resistance. [Cardio Vasc Diabetol] Abstract | Full Article

Mesenchymal Stem Cells Inhibit Multiple Myeloma Cells via the Fas-L/Fas Pathway
Researchers used a standard disseminated multiple myeloma (MM) model in mice to identify the in vivo effects of intravenous mesenchymal stem cell (MSC) infusion. In addition, a series of in vitro co-culture assays were performed to explore whether Fas/Fas Ligand (Fas-L) is involved in the inhibitory effects of MSCs on MM cells. [Stem Cell Res Ther] Abstract | Full Article

Isolation of Human Adipose-Derived Stromal Cells Using Laser-Assisted Liposuction and Their Therapeutic Potential in Regenerative Medicine
Adipose-derived stromal cells were harvested from laser-assisted lipoaspirate and suction-assisted lipoaspirate. Next, in vitro parameters of cell yield, cell viability and proliferation, surface marker phenotype, osteogenic differentiation, and adipogenic differentiation were performed. Finally, in vivo bone formation was assessed using a critical-sized cranial defect in athymic nude mice. [Stem Cell Transl Med] Abstract

Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
 
REVIEWS
In Vivo Reprogramming in Inflammatory Bowel Disease
The authors present a review of recent literature and a perspective of in vivo reprogramming in inflammatory bowel disease using bacterial vectors and analyze the rationale for such approach. [Gene Ther] Abstract

Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research field.

Read White Paper - STEMSOFT Software Inc.:  Your Inspection Workhorse.
 
SCIENCE NEWS
Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T
Sangamo BioSciences, Inc. announced the presentation of new data from its ongoing Phase II clinical trial (SB-728-902 Cohort 5) to evaluate a single infusion of Sangamo’s novel ZFP Therapeutic®, SB-728-T, for the treatment of HIV/AIDS. The data demonstrated functional control of the virus at or below the limit of detection in CCR5 delta-32 heterozygote HIV-infected subjects treated with SB-728-T. [Press release from Sangamo BioSciences, Inc. discussing research presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver] Press Release

Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase II Results
Chimerix, Inc. announced the results from its exploratory Phase II Study 202 evaluating brincidofovir (CMX001) in hematopoietic cell transplant recipients with early adenovirus infection. [Press release from Chimerix, Inc. discussing research presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver] Press Release

Save 20% Off the Standard Rate to Attend IBC’s Cell Therapy Bioprocessing Event: Mention Priority Code B13188CONNEXON when you register.
 
POLICY
Advisers Declare Italian Stem-Cell Therapy ‘Unscientific’
A scientific advisory committee in Italy gave a decided thumbs down to a controversial stem-cell treatment slated for a €3 million (US $4 million), government-sponsored clinical trial. The committee had been appointed by the health minister to evaluate the clinical protocol proposed by the Brescia-based Stamina Foundation, which developed the therapy. [The Italian Medicines Agency, Italy] Press Release

Sequester Cuts May Have Driven NIH Grant Success Rates Down to 14% in 2013
The automatic spending cuts and other reductions to the National Institutes of Health’s (NIH’s) budget this year have caused slightly less damage than expected, NIH Director Francis Collins said yesterday. Preliminary data show that about 50 more grants were funded than projected, he said at a forum sponsored by Research!America. But success rates may have plunged even further than the agency predicted. [National Institutes of Health, United States] Press Release

U.K. Parliamentarians Urge Government to Reshape Push for Open-Access Publishing
British parliamentarians are urging the government of the United Kingdom to alter its plans for transitioning to open-access (OA) publishing of research results. In a report released today, a committee of the House of Commons says the government should encourage greater use of free institutional repositories, rather than OA journals that charge per-paper fees for publishing. [House of Commons, United Kingdom] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
 
BUSINESS
Sernova and Medicyte to Collaborate on Cell-Based Therapy to Treat Hemophilia
Sernova Corp. and Medicyte GmbH announced that the companies have entered into a Material Transfer Agreement to jointly evaluate the use of Medicyte’s upcyte® cells in Sernova’s Cell Pouch™ for the treatment of patients with hemophilia A. [Sernova Corp.] Press Release

Cell Therapy Catapult & Roslin Cells to Create Clinical Grade Stem Cells to Accelerate Research into New Treatments
The Cell Therapy Catapult and Roslin Cells have partnered to establish a source of clinical grade induced pluripotent stem cells banked according to Good Manufacturing Practice in the UK. [Roslin Cells]
Press Release

Pluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery Disease Exclusive Rights to Treat Peripheral Artery Disease with Placental Cells in the U.S.
Pluristem Therapeutics Inc. announced that the company has completed a major step in its intellectual property strategy: the United States Patent and Trademark Office has granted the Company U.S. Patent 8,529,888. [Pluristem Therapeutics Inc.] Press Release

Weill Cornell Medical College Receives $100 Million Gift from Joan and Sanford I. Weill and the Weill Family Foundation to Launch New Capital Campaign
Weill Cornell Medical College announced that it has received a $100 million gift from longtime benefactors Joan and Sanford I. Weill and the Weill Family Foundation to launch the Medical College’s $300 million Driving Discoveries, Changing Lives campaign dedicated to using the most advanced scientific approaches to rapidly translate research breakthroughs into innovative treatments and therapies for patients. [Weill Cornell Medical College] Press Release

Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
Adaptive Biotechnologies announced that it received a $2.53 million Phase II Small Business Innovation Research award from the National Heart, Lung, and Blood Institute, a division of the NIH, to commercialize a test to measure the ability of a cancer patient’s adaptive immune system to fight infection after a cord blood transplant. [PR Newswire Association LLC] Press Release

First Patient Treated in Groundbreaking Stem Cell Therapy Trial for Heart Attack
Canadian researchers have treated the first patient in a world-first clinical trial using genetically enhanced stem cells to repair damaged heart muscle after a major heart attack. The formal name of the trial is ENACT-AMI, which stands for “Enhanced Angiogenic Cell Therapy – Acute Myocardial Infarction.” [Ottawa Hospital Research Institute] Press Release

NeoStem Receives Notification of Second Year Grant Award for Phase II Clinical Study of VSELTM Technology in Periodontitis
NeoStem, Inc. announced that it has been awarded funds for the second year of a two year grant totaling $1,221,854 for “Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL),” from the National Institute of Dental & Craniofacial Research, a division of the National Institutes of Health. [Neostem, Inc.] Press Release

StemCells, Inc. Announces First High-Dose Patient Transplanted in Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
StemCells, Inc. announced dosing of the first high-dose patient in the company’s Phase I/II clinical trial in dry age-related macular degeneration. The patient, the fifth overall in the 16-patient trial, was transplanted yesterday with one million HuCNS-SC® cells (purified human neural stem cells). [StemCells, Inc.] Press Release
 
NIH
National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting (FR Doc No: 2013-21943)

National Institute of Biomedical Imaging and Bioengineering Amended; Notice of Meeting (FR Doc No: 2013-21944)

Center For Scientific Review; Notice of Closed Meetings (FR Doc No: 2013-22052)

Government-Owned Inventions; Availability for Licensing (FR Doc No: 2013-22264)
 
CBER
Agenda – Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine
 
REGULATORY
Food and Drug Administration (United States)

Agency Information Collection Activities; Proposed Collection; Comment Request; Recommended Glossary and Educational Outreach to Support Use of Symbols on Labels and in Labeling of In Vitro Diagnostic Devices Intended for Professional Use (FR Doc No: 2013-22110)
 
EVENTS
NEW Cell Symposia: Using Stem Cells to Model and Treat Human Disease
November 21-23, 2013
Los Angeles, United States


Visit our events page to see a complete list of events in the cell, gene and immunotherapy community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Stem Cell Research (Tsinghua University Graduate School at Shenzhen)

Doctoral Position in Bioengineering (University of Genoa)

Postdoctoral Position – Leukemia Biology (Northwestern University)

Cellular Therapy Lab Specialist (University of Texas Medical School at Houston)

Postdoctoral Research Fellow – Bioengineering (Fred Hutchinson Cancer Research Center)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Position – Neurosteroids and Neural Stem Cells in Developing Brain (Children’s National Medical Center)

Postdoctoral Positions – AIDS Vaccine and Human Gene Therapy (GeneCure Biotechnologies)

Postdoctoral Appointee – Cell Cycle Regulation in Tumor Stem Cells (Rutgers University, Rutgers Cancer Institute of New Jersey)

Research Associate – Cardioprotection and Myocardium Repair by Gene or Cell Therapy (University of Louisville)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

SUBSCRIBER TOOLS:Subscribe Archives Twitter Facebook
Profile Center | Connexon Publications | Article Submission | Contact Us